Mesalamine Capsule, Delayed Release
Product Images NDC 0093-5907

2 FDA label images from Teva Pharmaceuticals Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Mesalamine (NDC 0093-5907). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (Image 1)

1 (Image 1)
Chemical structure of mesalamine, depicting a benzene ring with amino, hydroxyl, and carboxyl functional groups characteristic of this active pharmaceutical ingredient.*
FDA Label Image

1 (Image 2)

1 (Image 2)
Mesalamine Delayed-Release 400 mg capsules label by Teva Pharmaceuticals USA. The label indicates the product is a human prescription drug with 180 capsules per package. It states that each delayed-release capsule contains 400 mg mesalamine and includes directions for oral administration without breaking or chewing. The label features NDC 0093-5907, storage instructions, and a statement that it is not bioequivalent to Asacol HD.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.